Enabling a four-fold increase in titer for mAb manufacturing using Syngene’s platform process

Learn how Syngene’s platform approach to mAb manufacturing helped a biopharma company achieve a four-fold increase in titer in less than a year, resulting in improved efficiency and reduced costs.

Author

Latest Blogs

Global clinical development network showing India connected to clinical sites, hospitals, laboratories, data systems, and regulatory pathways for scalable global clinical trials.

Clinical development planning in India: From execution hub to strategic trial partner

Supply chain resilience in multi-continent biopharma manufacturing

Future-Ready QC Labs in Pharma 4.0: How Automation, Biometrics, and VR Are Redefining Quality Standards in India

Syngene booth at CPHI Japan 2026 with visitors and team members in discussion

CPHI Japan 2026 Takeaways: Why supply chain diversification is redefining CDMO trust in Japan

Decoding the FDA’s AMT program through process analytical technology

Infographic showing gene editing applications across the drug development pipeline.

Gene editing in 2025: from CRISPR to next generation platforms